Biora Therapeutics Past Earnings Performance
Past criteria checks 0/6
Biora Therapeutics has been growing earnings at an average annual rate of 21.3%, while the Biotechs industry saw earnings growing at 19.1% annually. Revenues have been declining at an average rate of 87.6% per year.
Key information
21.3%
Earnings growth rate
85.6%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | -87.6% |
| Return on equity | n/a |
| Net Margin | -3,988.1% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Revenue & Expenses Breakdown
How Biora Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 1 | -36 | 35 | 26 |
| 30 Jun 24 | 1 | -87 | 37 | 31 |
| 31 Mar 24 | 1 | -111 | 38 | 30 |
| 31 Dec 23 | 0 | -124 | 37 | 30 |
| 30 Sep 23 | 0 | -122 | 38 | 29 |
| 30 Jun 23 | 0 | -64 | 33 | 25 |
| 31 Mar 23 | 0 | -52 | 33 | 25 |
| 31 Dec 22 | 0 | -49 | 38 | 24 |
| 30 Sep 22 | 1 | -118 | 42 | 27 |
| 30 Jun 22 | 1 | -140 | 52 | 33 |
| 31 Mar 22 | 1 | -176 | 67 | 41 |
| 31 Dec 21 | 1 | -179 | 73 | 46 |
| 30 Sep 21 | 1 | -146 | 76 | 49 |
| 30 Jun 21 | 1 | -142 | 75 | 49 |
| 31 Mar 21 | -16 | -106 | 48 | 48 |
| 31 Dec 20 | 0 | -105 | 60 | 48 |
| 30 Sep 20 | 21 | -142 | 75 | 51 |
| 30 Jun 20 | 39 | -207 | 89 | 55 |
| 31 Mar 20 | 113 | -218 | 122 | 59 |
| 31 Dec 19 | 144 | -229 | 120 | 63 |
| 30 Sep 19 | 120 | -211 | 116 | 63 |
| 31 Dec 18 | 128 | -129 | 101 | 49 |
Quality Earnings: BIOR is currently unprofitable.
Growing Profit Margin: BIOR is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: BIOR is unprofitable, but has reduced losses over the past 5 years at a rate of 21.3% per year.
Accelerating Growth: Unable to compare BIOR's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: BIOR is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).
Return on Equity
High ROE: BIOR's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.